Summary
Regeneron Pharmaceuticals first-in-class investigational allergen-blocking monoclonal antibodies (mAbs) met their primary endpoints in two Phase III trials in adults with moderate-to-severe cat or birch allergies.
In the cat allergen trial, patients received a single dose of REGN1908 and REGN1909,…
Source: Yahoo Finance
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
